MIRM 8-K: Fda approval
Mirum Pharmaceuticals
Filed with the SEC on · accession 0001759425-26-000064
MIRM filed a 8-K (current report) with the SEC on Nov 10, 2026. Mirum Pharmaceuticals announced that its Phase 3 AZURE-4 study of brelovitug met its primary endpoint in chronic hepatitis delta virus, with 59% and 44% of patients in the 300 mg QW and 900 mg Q4W arms achieving the combined virologic response and ALT normalization endpoint versus 0% in the…
Summary of the filing
Mirum Pharmaceuticals announced that its Phase 3 AZURE-4 study of brelovitug met its primary endpoint in chronic hepatitis delta virus, with 59% and 44% of patients in the 300 mg QW and 900 mg Q4W arms achieving the combined virologic response and ALT normalization endpoint versus 0% in the delayed-treatment arm. The company plans to submit a BLA to the FDA in the first half of 2027 with a potential U.S. launch in Q4 2027.
Key details
✦ Ask GOAX AI about this filing — what it means for MIRM, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for MIRM?
Click hereFrequently asked questions
What did MIRM file with the SEC on Nov 10, 2026?
MIRM filed a 8-K (Fda approval). Mirum Pharmaceuticals announced that its Phase 3 AZURE-4 study of brelovitug met its primary endpoint in chronic hepatitis delta virus, with 59% and 44% of patients in the 300 mg QW and 900 mg Q4W arms achieving the combined virologic response and ALT normalization endpoint versus 0% in the delayed-treatment arm. The company plans to submit a BLA to the FDA in the first half of 2027 with a potential U.S. launch in Q4 2027.
What does a fda approval mean for MIRM stock?
For a small biotech one drug can be most of the company’s value. Approval opens sales; a rejection (complete response letter) can delay it by years.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other MIRM SEC filings
- 8-K · SEC filingNov 3, 2026
- 10-Q · Executive departureNov 3, 2026
- 8-K · Fda approvalOct 26, 2026
- 8-K · Fda approvalOct 13, 2026
- 8-K · Fda approvalSep 28, 2026
- 8-K · Executive departureSep 8, 2026
- SCHEDULE 13G/A · SEC filingAug 13, 2026
- 10-Q · SEC filingAug 5, 2026
- 8-K · SEC filingAug 5, 2026
- 8-K · SEC filingJun 18, 2026
Get alerts when MIRM files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days